Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers
about
R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and MetastasisOncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomasp21-activated Kinases (PAKs) Mediate the Phosphorylation of PREX2 Protein to Initiate Feedback Inhibition of Rac1 GTPase.P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer.Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion.Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.Structure, biochemistry, and biology of PAK kinases.The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.PREX1 Protein Function Is Negatively Regulated Downstream of Receptor Tyrosine Kinase Activation by p21-activated Kinases (PAKs).MicroRNA-200c is involved in proliferation of gastric cancer by directly repressing p27Kip1.Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways.A key role for Rac and Pak signaling in neutrophil extracellular traps (NETs) formation defines a new potential therapeutic target.KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?Targeting p21 activated kinase 1 (Pak1) to PAKup Pancreatic Cancer.
P2860
Q28265491-D46F95AE-C15E-4224-9277-A7D8E631AE73Q35612218-A5E8E453-E69E-4202-90FB-5ACE17E4FB39Q36323481-608D4FEE-3699-404F-8735-B52848EBC073Q36687323-814E626B-F793-4471-8D4F-7BF843ADBB8CQ36814030-9508188E-D0CF-4AFD-A29F-A427EC4FE61FQ37702754-A6770D92-D429-457E-B56C-FB3B0DE99D64Q38722567-EBDF3829-4930-48E2-B50C-DFDB1DE6153FQ38775171-B84E7CD5-CC6D-49D7-B445-30CA4ACB0852Q38779105-CA6B5FFA-CE02-4E57-A14E-23879E74FCCCQ38798826-D1A80365-D7CF-4E57-8598-83DD3A533520Q39534941-9ADAAD52-2CB5-44D5-B0B0-5EE320D30A73Q41682632-6279BFFA-31F4-4E48-BA7B-6B674D905A86Q45907489-3CE69A89-6216-4954-BED5-4F0AA59FF541Q46264202-B4AF9935-B61C-4816-A6CF-C0B4BFBE8633Q47563012-C030DA94-5FE5-4C1B-9EE3-D2C681A850CBQ48635490-4B5C82A4-49C7-474A-8AF3-F8D226167FCEQ53768938-896185F8-0E88-4CF4-BFD3-3BC2E7D5B543
P2860
Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Molecular pathways: targeting ...... ignaling in RAS-driven cancers
@ast
Molecular pathways: targeting ...... ignaling in RAS-driven cancers
@en
Molecular pathways: targeting ...... ignaling in RAS-driven cancers
@nl
type
label
Molecular pathways: targeting ...... ignaling in RAS-driven cancers
@ast
Molecular pathways: targeting ...... ignaling in RAS-driven cancers
@en
Molecular pathways: targeting ...... ignaling in RAS-driven cancers
@nl
prefLabel
Molecular pathways: targeting ...... ignaling in RAS-driven cancers
@ast
Molecular pathways: targeting ...... ignaling in RAS-driven cancers
@en
Molecular pathways: targeting ...... ignaling in RAS-driven cancers
@nl
P2093
P2860
P1476
Molecular pathways: targeting ...... ignaling in RAS-driven cancers
@en
P2093
Channing J Der
Hoi Yee Chow
Nicole M Baker
P2860
P304
P356
10.1158/1078-0432.CCR-13-1727
P407
P577
2014-09-01T00:00:00Z